Vivos Inc financial data

Symbol
RDGL on OTC
Location
719 Jadwin Avenue, Richland, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
ADVANCED MEDICAL ISOTOPE Corp (to 12/18/2017)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.76K % +40.9%
Debt-to-equity 6.02 % -30.8%
Return On Equity -186 % +4.92%
Return On Assets -176 % +2.52%
Operating Margin -9.3K % +35.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 453M shares +16.3%
Common Stock, Shares, Outstanding 441M shares +13.7%
Entity Public Float 78.8M USD +115%
Common Stock, Value, Issued 441K USD +13.7%
Weighted Average Number of Shares Outstanding, Basic 410M shares +11.1%
Weighted Average Number of Shares Outstanding, Diluted 410M shares +11.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 28K USD +43.6%
Research and Development Expense 325K USD -55.7%
General and Administrative Expense 242K USD +45.9%
Operating Income (Loss) -2.6M USD +6.76%
Nonoperating Income (Expense) -306K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.91M USD -0.54%
Net Income (Loss) Attributable to Parent -2.91M USD -0.54%
Earnings Per Share, Basic -0.01 USD/shares 0%
Earnings Per Share, Diluted -0.01 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.21M USD +39%
Accounts Receivable, after Allowance for Credit Loss, Current 10.3K USD +47.5%
Assets, Current 2.23M USD +38.7%
Assets 2.23M USD +38.7%
Liabilities, Current 86.2K USD -64.8%
Liabilities 86.2K USD -64.8%
Common Stocks, Including Additional Paid in Capital 130K USD
Retained Earnings (Accumulated Deficit) -85.4M USD -3.53%
Stockholders' Equity Attributable to Parent 2.15M USD +57.3%
Liabilities and Equity 2.23M USD +38.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -351K USD -19.7%
Net Cash Provided by (Used in) Financing Activities 130K USD
Common Stock, Shares Authorized 950M shares 0%
Common Stock, Shares, Issued 441M shares +13.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -221K USD +24.6%
Deferred Tax Assets, Valuation Allowance 7.26M USD +6.14%
Deferred Tax Assets, Operating Loss Carryforwards 7.26M USD +6.14%
Preferred Stock, Shares Authorized 20M shares 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%